Citable company snapshot
AbbVie's latest SEC-sourced 2026-03-31 period shows $15.00B in revenue and $695.00M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:Revenues | Mar 31, 2026 | $15.00B | $16.62B | -9.7% |
| xbrl:GrossProfit | Dec 31, 2025 | $12.07B | $10.71B | +12.7% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $3.99B | $4.54B | -12.2% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $695.00M | $1.82B | -61.7% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $3.83B | $5.22B | -26.6% |
| Free Cash Flow (computed) | Mar 31, 2026 | $3.56B | $4.89B | -27.1% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 8, 2026; accession 0001551152-26-000017.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
